Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News
Das Kupferangebot bricht ein - und dieser neue Fund kommt genau zur richtigen Zeit
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A407YS | ISIN: US8162123025 | Ticker-Symbol: 1S70
Frankfurt
08.08.25 | 08:53
8,650 Euro
-6,49 % -0,600
1-Jahres-Chart
CARTESIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CARTESIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,6509,45008.08.

Aktuelle News zur CARTESIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCartesian Therapeutics GAAP EPS of $0.50 beats by $1.31, revenue of $0.3M misses by $0.51M1
DoCartesian Therapeutics, Inc. - 10-Q, Quarterly Report1
DoCartesian Therapeutics, Inc. - 8-K, Current Report3
DiCartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants120FREDERICK, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases...
► Artikel lesen
09.07.Wedbush initiates coverage on Cartesian Therapeutics stock with Outperform rating2
09.07.Cartesian Therapeutics: Wedbush startet Coverage mit "Outperform"3
16.06.Cartesian Therapeutics, Inc. - 8-K, Current Report6
03.06.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants172FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases...
► Artikel lesen
CARTESIAN THERAPEUTICS Aktie jetzt für 0€ handeln
30.05.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis393FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune...
► Artikel lesen
30.05.Cartesian Therapeutics, Inc. - 8-K, Current Report-
08.05.Cartesian Therapeutics GAAP EPS of -$0.68 beats by $0.03, revenue of $1.1M beats by $0.41M4
08.05.Cartesian Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
08.05.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update179Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial ...
► Artikel lesen
08.05.Cartesian Therapeutics, Inc. - 10-Q, Quarterly Report1
08.05.Cartesian Therapeutics, Inc. - 8-K, Current Report1
02.05.Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants172FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune...
► Artikel lesen
29.04.Cartesian Therapeutics, Inc. - 8-K, Current Report1
08.04.Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients1
08.04.Cartesian Therapeutics, Inc.: Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial193After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest...
► Artikel lesen
08.04.Cartesian Therapeutics, Inc. - 8-K, Current Report1
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1